Search results for "Small-cell carcinoma"

showing 10 items of 12 documents

A rare rarity: neuroendocrine tumor of the esophagus

2019

Abstract Esophageal Neuroendocrine tumors (NETs) are rare, aggressive and lacking specific symptoms. This causes a diagnostic delay, worsening the prognosis. Numerous cases are reported in literature, without a consensus on the management. Our aim was to clarify epidemiology, clinical presentation, diagnostic, therapeutic management of esophageal NETs. Extensive literature search identified a total of 226 articles. One hundred twenty-five articles (n = 1676) met the inclusion criteria, showing that: the incidence of esophageal NET varies geographically; men (60–70 years) are more affected; smoking and alcohol abuse are the major risk factors; dysphagia, weight loss, appetite loss are the mo…

0301 basic medicinemedicine.medical_specialtyCarcinoid tumorsesophageal neoplasmsNeuroendocrine tumorsSmall-cell carcinomaGastroenterology03 medical and health sciences0302 clinical medicinegastroenteropancreatic NETInternal medicineEpidemiologymedicinerisk factorsesophageal NEC; gastroenteropancreatic NET; large cell esophageal NEN; MANEC; small cell carcinoma; delayed diagnosis; esophageal neoplasms; humans; neuroendocrine tumors; prognosis; rare diseases; risk factorsEsophagusStage (cooking)esophageal NECdelayed diagnosishumanssmall cell carcinomabusiness.industryLarge cellMANECrare diseasesHematologymedicine.diseaseDysphagia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesislarge cell esophageal NENprognosismedicine.symptomneuroendocrine tumorsbusiness
researchProduct

Solid variant of mammary "adenoid cystic carcinoma with basaloid features" merging with "small cell carcinoma"

2005

We describe a rare case of a solid variant of a mammary adenoid cystic carcinoma with basaloid features (sbACC) and its coexistence with a "small cell" carcinoma (SCC), identified and confirmed by histological and immunohistochemical observations: the absence of glandular structures and PAS-positive globules, positivity for neuroendocrine markers (NSE, synaptophysin and chromogranin), and negativity for 34betaE12 and SMA actin were the aspects suggesting the presence of SCC. Furthermore, positivity for CD10 was found both in sbA CC and in SCC, supporting the hypothesis that the two components share the same histogenetic myoepithelial origin and represent an example of dedifferentiation alon…

AdultPathologymedicine.medical_specialtyAdenoid cystic carcinoma2734Breast NeoplasmsBiologyHistogenesisSettore MED/08 - Anatomia PatologicaMastectomy SegmentalSmall-cell carcinomaPathology and Forensic MedicineNeoplasms Multiple PrimaryBiomarkers TumormedicineCarcinomaHumansBreastCarcinoma Small CellneoplasmsSmall cell carcinomaMyoepithelial cellChromogranin ABasaloid adenoid cystic carcinomaCell BiologyPeriodic Acid-Schiff Reactionmedicine.diseaseCarcinoma Adenoid CysticImmunohistochemistrystomatognathic diseasesSettore MED/18 - Chirurgia GeneraleCarcinoma Basal CellChemotherapy AdjuvantAxillaSynaptophysinbiology.proteinLymph Node ExcisionImmunohistochemistryFemaleBasaloid adenoid cystic carcinoma; Breast; Small cell carcinoma; Adult; Axilla; Biomarkers Tumor; Breast Neoplasms; Carcinoma Adenoid Cystic; Carcinoma Basal Cell; Carcinoma Small Cell; Chemotherapy Adjuvant; Female; Humans; Immunohistochemistry; Lymph Node Excision; Mastectomy Segmental; Neoplasms Multiple Primary; Periodic Acid-Schiff Reaction; 2734Breast NeoplasmHuman
researchProduct

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model.

2000

OBJECTIVE: Percutaneous ethanol injection may prolong the survival of patients with small hepatocellular carcinoma associated with cirrhosis. The aim was to identify prognostic factors of survival and of local recurrence, as well as separate new lesions. METHODS: We performed Cox regression analysis in 115 consecutive patients with hepatocellular carcinoma (81 Child-Pugh class A, 34 Child-Pugh class B) treated by percutaneous ethanol injection. The validity of the model was tested by comparing predicted and observed survival in 105 independent patients from an external series. RESULTS: Overall survival rates were 89%, 63%, and 43% at 1, 2, and 3 yr, respectively. The 1-, 2-, and 3-yr surviv…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentInjections IntralesionalSmall-cell carcinomaGastroenterologyLiver Function TestsInternal medicinemedicineCarcinomaHumansSurvival rateSerum AlbuminAgedHepatologymedicine.diagnostic_testEthanolbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesSurgerySurvival RateHepatocellular carcinomaFemalePercutaneous ethanol injectionbusinessLiver function testsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?

2019

Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease. In most cases, prostate cancer essentially depends on androgen receptor signaling axis, even in castration-resistant setting, and hence may be targeted by second generation hormonal therapy. However, a subset of patients bears androgen-independent cancer biology with a short-term response to hormonal treatment, early and extensive visceral metastases, low PSA levels and poor outcomes. Identification and specific management of these rapidly fatal malignancies is of an unmet medical ne…

Male0301 basic medicineOncologymedicine.medical_specialtyAntineoplastic Agents HormonalDiseaseNeuroendocrine differentiationSmall-cell carcinoma03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingResponse rate (survey)business.industryGeneral Medicinemedicine.diseaseAndrogen receptorProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyReceptors Androgen030220 oncology & carcinogenesisAndrogensAdenocarcinomaHormonal therapybusinessCancer Treatment Reviews
researchProduct

Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.

2009

Abstract Background Transmission of donor-derived cancer by organ transplantation is rare, but the risk has been increasing due to the aging donor pool. Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor with the tendency to spread. Herein we have demonstrated different approaches to treat organ recipients with transmitted tumors. Methods and Results Grafts were retrieved from a decreased donor without any history of previous diseases. Autopsy was not performed after donation. The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound. After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAutopsyAntineoplastic AgentsSmall-cell carcinomaNephrectomyOrgan transplantationCarboplatinalpha 1-Antitrypsin DeficiencyBiopsymedicineCarcinomaHumansCarcinoma Small CellNeoplasm MetastasisEtoposideTransplantationChemotherapymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseaseDNA FingerprintingEmbolization TherapeuticKidney TransplantationTissue DonorsSurgeryLiver TransplantationTransplantationHeart TransplantationSurgerybusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis.

2001

Small-cell lung cancer (SCLC) carries a bad prognosis despite good initial response to chemotherapy. It is therefore important to identify molecular markers that influence survival as potential new therapeutic targets. In our study, expression of the tyrosine kinase c-erbB-2 (HER2/neu) receptor in tumor tissues of 107 consecutive newly diagnosed patients with primary SCLC was quantified using a monoclonal antibody directed against the c-terminal domain of c-erbB-2. A clear-cut positive expression of c-erbB-2 was observed in 13% of patients. Surprisingly, c-erbB-2 was an independent prognostic factor (RR = 2.16; p = 0.014) when a proportional-hazard model was adjusted to stage (limited vs. e…

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsReceptor ErbB-2medicine.medical_treatmentSmall-cell carcinomaDisease-Free SurvivalSex FactorsInternal medicinemedicineCarcinomaHumansCarcinoma Small CellLung cancerneoplasmsAgedProportional Hazards ModelsChemotherapyPerformance statusL-Lactate DehydrogenaseProportional hazards modelbusiness.industryAge FactorsCancerAntibodies MonoclonalMiddle Agedmedicine.diseasePrognosisImmunohistochemistryProtein Structure TertiaryTreatment OutcomeOncologyPhosphopyruvate HydrataseImmunohistochemistryFemalebusinessInternational journal of cancer
researchProduct

Histopathologic risk factors in oral and oropharyngeal squamous cell carcinoma variants: An update with special reference to HPV-related carcinomas

2014

Accurate identification of the microscopic risk factors of oral and oropharyngeal (OP) squamous cell carcinomas (SCC) and their morphologic variants is of at most importance, as these generally determine treatment modalities, prognosis and overall patient outcome. The great majority of oral and oropharyngeal squamous cell carcinomas are microscopically described as kerartinizing squamous cell carcinoma (KSCC). They bear certain resemblance to keratinizing stratified squamous epithelium. Tobacco habits and excessive consumption of alcoholic beverages have been considered to be the main etiologic agents in these carcinomas. The tumors occurred in older patients more commonly affected the oral…

Oncologymedicine.medical_specialtyPathologyOdontologíaStratified squamous epitheliumReviewSmall-cell carcinomaRisk FactorsInternal medicinemedicineCarcinomaHumansStage (cooking)Basaloid Squamous Cell CarcinomaGeneral DentistryMouth neoplasmOral Medicine and Pathologybusiness.industryPapillomavirus Infections:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludHead and neck squamous-cell carcinomastomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOropharyngeal NeoplasmOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellSurgeryMouth NeoplasmsbusinessMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer

2006

The paraneoplastic amphiphysin(+) stiff-person syndrome (SPS) has so far only been described in women with breast adenocarcinoma. Here, we describe the rare case of a female patient with antiamphiphysin(+) SPS due to small cell cancer of the lung.

Pathologymedicine.medical_specialtyLung NeoplasmseducationNerve Tissue ProteinsStiff-Person SyndromeBreast AdenocarcinomaSmall-cell carcinomafluids and secretionsmedicineCarcinomaHumansCarcinoma Small CellLung cancerAutoantibodiesLungElectromyographybusiness.industryfungiRespiratory diseaseMiddle Agedequipment and suppliesmedicine.diseasemedicine.anatomical_structureNeurologyAmphiphysinFemaleNeurology (clinical)businessStiff person syndromeMovement Disorders
researchProduct

Ziliarkörpermetastase als Ersthinweis auf ein kleinzelliges Bronchialkarzinom1

2000

BACKGROUND About 3-10% of patients suffering from metastatic disease develop metastatic choroidal tumors. In this case report ocular symptoms were the first sign of a systemic malignancy. CASE REPORT A 65-year old man complained of an increasing painful redness of his left eye. He showed a white mass with 10 mm in thickness in the temporal chamber angle with "pseudohypopyon" and secondary glaucoma. Because of increasing pain the eye was removed. Histologic examination showed a small cell carcinoma of the ciliary body with high malignancy, which most probably has to be seen as a metastasis of a carcinoma of the lung, which was detected by internal examination concurrently. In addition, a met…

Pathologymedicine.medical_specialtyLungAdrenal glandbusiness.industrymedicine.diseaseMalignancySmall-cell carcinomaeye diseasesMetastasisOphthalmologymedicine.anatomical_structureCiliary bodyCarcinomamedicinebusinessAmelanotic melanomaKlinische Monatsblätter für Augenheilkunde
researchProduct